Published in Invest Ophthalmol Vis Sci on December 05, 2008
Inhibition of retinal detachment-induced apoptosis in photoreceptors by a small peptide inhibitor of the fas receptor. Invest Ophthalmol Vis Sci (2009) 1.06
XIAP therapy increases survival of transplanted rod precursors in a degenerating host retina. Invest Ophthalmol Vis Sci (2011) 1.01
RhoA inactivation prevents photoreceptor axon retraction in an in vitro model of acute retinal detachment. Invest Ophthalmol Vis Sci (2011) 0.90
Up-regulation of tumor necrosis factor superfamily genes in early phases of photoreceptor degeneration. PLoS One (2013) 0.87
Strain difference in photoreceptor cell death after retinal detachment in mice. Invest Ophthalmol Vis Sci (2014) 0.84
Caspase inhibition with XIAP as an adjunct to AAV vector gene-replacement therapy: improving efficacy and prolonging the treatment window. PLoS One (2012) 0.83
Retinal gene therapy using adeno-associated viral vectors: multiple applications for a small virus. Hum Gene Ther (2014) 0.77
Caspase-9 mediates photoreceptor death after blunt ocular trauma. Invest Ophthalmol Vis Sci (2014) 0.76
Advances in Gene Therapy for Diseases of the Eye. Hum Gene Ther (2016) 0.75
Gene therapy approaches for the treatment of retinal disorders. Discov Med (2016) 0.75
FAS apoptotic inhibitory molecule 2 is a stress-induced intrinsic neuroprotective factor in the retina. Cell Death Differ (2017) 0.75
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods (2002) 5.30
The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene (2003) 2.71
Apoptotic photoreceptor degeneration in experimental retinal detachment. Invest Ophthalmol Vis Sci (1995) 2.24
Recovery of visual acuity after retinal detachment involving the macula. Trans Am Ophthalmol Soc (1982) 2.17
Apoptotic photoreceptor cell death after traumatic retinal detachment in humans. Arch Ophthalmol (1995) 1.85
Production and purification of recombinant adeno-associated virus. Methods Enzymol (2000) 1.66
Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J Biol Chem (2000) 1.56
IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. Mol Cell Biol (2002) 1.51
Evaluation and management of suspected retinal detachment. Am Fam Physician (2004) 1.47
Retinal detachment in the cat: the outer nuclear and outer plexiform layers. Invest Ophthalmol Vis Sci (1983) 1.45
Caspase activation in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci (2003) 1.40
Neurite outgrowth from bipolar and horizontal cells after experimental retinal detachment. Invest Ophthalmol Vis Sci (1998) 1.39
Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther (2002) 1.26
FAS-mediated apoptosis and its relation to intrinsic pathway activation in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci (2004) 1.24
XIAP protection of photoreceptors in animal models of retinitis pigmentosa. PLoS One (2007) 1.17
Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus. J Neurosci (1999) 1.16
The ability of rapid retinal reattachment to stop or reverse the cellular and molecular events initiated by detachment. Invest Ophthalmol Vis Sci (2002) 1.09
Structural and functional protection of photoreceptors from MNU-induced retinal degeneration by the X-linked inhibitor of apoptosis. Invest Ophthalmol Vis Sci (2003) 1.08
AAV-mediated delivery of the caspase inhibitor XIAP protects against cisplatin ototoxicity. Otol Neurotol (2006) 1.07
Caspase activation. Biochem Soc Symp (2003) 1.02
Management of retinal detachment: a guide for non-ophthalmologists. BMJ (2008) 0.97
Role of inhibitor of apoptosis protein in gentamicin-induced cochlear hair cell damage. Neuroscience (2007) 0.96
The X-linked inhibitor of apoptosis (XIAP) prevents cell death in axotomized CNS neurons in vivo. Cell Death Differ (2000) 0.95
Protection against cisplatin-induced ototoxicity by adeno-associated virus-mediated delivery of the X-linked inhibitor of apoptosis protein is not dependent on caspase inhibition. Otol Neurotol (2007) 0.91
Attenuation of MPTP-induced neurotoxicity and behavioural impairment in NSE-XIAP transgenic mice. Neurobiol Dis (2003) 0.91
Binding pattern of anti-rhodopsin monoclonal antibodies to photoreceptor cells: an immunocytochemical study. Exp Eye Res (1989) 0.90
Opsin distribution and protein incorporation in photoreceptors after experimental retinal detachment. Exp Eye Res (1991) 0.88
XIAP-mediated neuroprotection in retinal ischemia. Gene Ther (2006) 0.87
Potential synergistic protection of retinal ganglion cells from axotomy-induced apoptosis by adenoviral administration of glial cell line-derived neurotrophic factor and X-chromosome-linked inhibitor of apoptosis. Neurobiol Dis (2002) 0.86
XIAP protects photoreceptors from n-methyl-n-nitrosourea-induced retinal degeneration. Adv Exp Med Biol (2003) 0.78
Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A (2008) 7.16
A muscleblind knockout model for myotonic dystrophy. Science (2003) 5.93
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods (2002) 5.30
Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther (2005) 4.74
DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature (2011) 3.90
Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol (2011) 3.79
Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med (2015) 3.16
Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther (2009) 3.07
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther (2008) 2.93
DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell (2012) 2.81
Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A (2013) 2.71
Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med (2009) 2.57
Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA). Mol Vis (2005) 2.55
Dicer inactivation leads to progressive functional and structural degeneration of the mouse retina. J Neurosci (2008) 2.50
Restoration of cone vision in a mouse model of achromatopsia. Nat Med (2007) 2.44
Gene therapy for red-green colour blindness in adult primates. Nature (2009) 2.44
Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78. Proc Natl Acad Sci U S A (2010) 2.40
Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol Ther (2005) 2.27
Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet (2010) 2.18
Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol Ther (2006) 2.13
Rescue of a mitochondrial deficiency causing Leber Hereditary Optic Neuropathy. Ann Neurol (2002) 2.13
Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci U S A (2012) 2.12
NOVEL CLASSIFICATION SYSTEM FOR COMBINED HAMARTOMA OF THE RETINA AND RETINAL PIGMENT EPITHELIUM. Retina (2017) 2.04
Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber's hereditary optic neuropathy in a mouse model. Proc Natl Acad Sci U S A (2012) 1.94
Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. Mol Ther (2011) 1.91
Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci (2003) 1.83
Pharmacological and rAAV gene therapy rescue of visual functions in a blind mouse model of Leber congenital amaurosis. PLoS Med (2005) 1.83
Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum Gene Ther (2006) 1.81
Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x-linked juvenile retinoschisis. Mol Ther (2005) 1.79
Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation. PLoS Med (2007) 1.79
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther (2010) 1.77
SOD2 knockdown mouse model of early AMD. Invest Ophthalmol Vis Sci (2007) 1.77
Paracentral acute middle maculopathy: a new variant of acute macular neuroretinopathy associated with retinal capillary ischemia. JAMA Ophthalmol (2013) 1.76
Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol Ther (2010) 1.75
A comprehensive review of retinal gene therapy. Mol Ther (2013) 1.70
SOD2 gene transfer protects against optic neuropathy induced by deficiency of complex I. Ann Neurol (2004) 1.70
AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDEbeta mutation. Invest Ophthalmol Vis Sci (2008) 1.68
Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital amaurosis. PLoS Med (2006) 1.67
Racial differences in age-related macular degeneration rates in the United States: a longitudinal analysis of a managed care network. Am J Ophthalmol (2011) 1.61
Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis (2008) 1.59
AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci (2002) 1.58
TrkB gene transfer protects retinal ganglion cells from axotomy-induced death in vivo. J Neurosci (2002) 1.51
Adeno-associated virus-vectored gene therapy for retinal disease. Hum Gene Ther (2005) 1.43
IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease. J Am Soc Nephrol (2005) 1.41
Suppression of mitochondrial oxidative stress provides long-term neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci (2007) 1.40
Light-driven cone arrestin translocation in cones of postnatal guanylate cyclase-1 knockout mouse retina treated with AAV-GC1. Invest Ophthalmol Vis Sci (2006) 1.39
Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death. Proc Natl Acad Sci U S A (2013) 1.36
Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse. PLoS One (2010) 1.33
Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS One (2013) 1.33
Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel. Hum Gene Ther (2010) 1.33
Predictors of visual outcome and choroidal neovascular membrane formation after traumatic choroidal rupture. Arch Ophthalmol (2006) 1.32
ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. Mol Ther (2011) 1.32
Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Invest Ophthalmol Vis Sci (2008) 1.31
ER stress is involved in T17M rhodopsin-induced retinal degeneration. Invest Ophthalmol Vis Sci (2012) 1.31
AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. PLoS One (2012) 1.28
Increased sensitivity to light-induced damage in a mouse model of autosomal dominant retinal disease. Invest Ophthalmol Vis Sci (2007) 1.27
Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther (2002) 1.26
Electroretinographic analyses of Rpe65-mutant rd12 mice: developing an in vivo bioassay for human gene therapy trials of Leber congenital amaurosis. Mol Vis (2007) 1.26
The mutant human ND4 subunit of complex I induces optic neuropathy in the mouse. Invest Ophthalmol Vis Sci (2007) 1.26
Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis. J Biol Chem (2006) 1.25
Long-term rescue of retinal structure and function by rhodopsin RNA replacement with a single adeno-associated viral vector in P23H RHO transgenic mice. Hum Gene Ther (2012) 1.24
FAS-mediated apoptosis and its relation to intrinsic pathway activation in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci (2004) 1.24
Comparative analysis of in vivo and in vitro AAV vector transduction in the neonatal mouse retina: effects of serotype and site of administration. Vision Res (2007) 1.24
Interleukin 10 attenuates neointimal proliferation and inflammation in aortic allografts by a heme oxygenase-dependent pathway. Proc Natl Acad Sci U S A (2005) 1.22
Molecular and cellular alterations induced by sustained expression of ciliary neurotrophic factor in a mouse model of retinitis pigmentosa. Invest Ophthalmol Vis Sci (2007) 1.22
Gene therapy prevents photoreceptor death and preserves retinal function in a Bardet-Biedl syndrome mouse model. Proc Natl Acad Sci U S A (2011) 1.22
AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa. Hum Gene Ther (2011) 1.20
Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice. Am J Pathol (2009) 1.19
Diabetic eNOS-knockout mice develop accelerated retinopathy. Invest Ophthalmol Vis Sci (2010) 1.18
Role of the Fas-signaling pathway in photoreceptor neuroprotection. Arch Ophthalmol (2007) 1.18
XIAP protection of photoreceptors in animal models of retinitis pigmentosa. PLoS One (2007) 1.17
Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. Hum Gene Ther (2005) 1.17
Effect of late-stage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin-deficient mouse. Mol Ther (2008) 1.17
The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina. Hum Gene Ther (2012) 1.16
Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye. Mol Vis (2009) 1.16
Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis. Invest Ophthalmol Vis Sci (2011) 1.16
Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. Invest Ophthalmol Vis Sci (2011) 1.15
Cone-specific expression using a human red opsin promoter in recombinant AAV. Vision Res (2007) 1.14
Efficiency and safety of AAV-mediated gene delivery of the human ND4 complex I subunit in the mouse visual system. Invest Ophthalmol Vis Sci (2009) 1.14
Optic neuropathy induced by reductions in mitochondrial superoxide dismutase. Invest Ophthalmol Vis Sci (2003) 1.13
Recombinant adeno-associated virus targets passenger gene expression to cones in primate retina. J Opt Soc Am A Opt Image Sci Vis (2007) 1.12
Molecular testing for hereditary retinal disease as part of clinical care. Arch Ophthalmol (2007) 1.12
Gene therapy for retinitis pigmentosa caused by MFRP mutations: human phenotype and preliminary proof of concept. Hum Gene Ther (2012) 1.12
Treatment of metastatic tumors of the choroid with proton beam irradiation. Ophthalmology (2005) 1.11
Transient photoreceptor deconstruction by CNTF enhances rAAV-mediated cone functional rescue in late stage CNGB3-achromatopsia. Mol Ther (2013) 1.10
Adeno-associated viral vectors and the retina. Adv Exp Med Biol (2008) 1.10
Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol Vis (2006) 1.10
Structural and functional protection of photoreceptors from MNU-induced retinal degeneration by the X-linked inhibitor of apoptosis. Invest Ophthalmol Vis Sci (2003) 1.08
Self-complementary AAV5 vector facilitates quicker transgene expression in photoreceptor and retinal pigment epithelial cells of normal mouse. Exp Eye Res (2010) 1.07
Intraocular CNTF reduces vision in normal rats in a dose-dependent manner. Invest Ophthalmol Vis Sci (2007) 1.07
Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. Elife (2013) 1.06
Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol (2003) 1.06
Inhibition of retinal detachment-induced apoptosis in photoreceptors by a small peptide inhibitor of the fas receptor. Invest Ophthalmol Vis Sci (2009) 1.06
Achromatopsia as a potential candidate for gene therapy. Adv Exp Med Biol (2010) 1.06
Interleukin-6 as a photoreceptor neuroprotectant in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci (2008) 1.06
Long-term suppression of neurodegeneration in chronic experimental optic neuritis: antioxidant gene therapy. Invest Ophthalmol Vis Sci (2007) 1.05